uniQure to Participate in Multiple Upcoming Industry Conferences in June

Rhea-AI Summary

uniQure, a leader in gene therapy, announced its upcoming participation in several virtual investor and scientific conferences, including the Jefferies Virtual Healthcare Conference and the European Hematology Association Virtual 2021. Key highlights include a Research & Development Day on June 22, 2021, focusing on advancements in gene therapy for CNS and rare liver-directed disorders. Additionally, the company will present pivotal data from the HOPE-B trial for etranacogene dezaparvovec targeting hemophilia B.

~ uniQure to host virtual Research & Development Day on June 22, 2021 ~

LEXINGTON, Mass. and AMSTERDAM, June 02, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming virtual investor and scientific conferences:

• Jefferies Virtual Healthcare Conference, June 1 - 4, 2021
  
  
  • Members of uniQure’s management team will participate in virtual one-on-one investor meetings throughout the day on Wednesday, June 2.
    
    
  • A fireside chat with Matt Kapusta, chief executive officer, will take place the same day from 8:30 to 8:55 a.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the Investors & Newsroom section of the uniQure website.
    
    
• European Hematology Association (EHA) Virtual 2021, June 7 - 13, 2021
  
  
  • uniQure will present two encore presentations respectively highlighting 26-week clinical data from the pivotal Phase 3 HOPE-B trial of the gene therapy etranacogene dezaparvovec in patients with severe to moderately severe hemophilia B.
    
    
    • An oral presentation entitled “26 Week Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua HFIX Variant; AMT-130) in Adults with Severe or Moderate-Severe Hemophilia B Treated in the Phase 3 HOPE-B Clinical Trial” will be available on June 11, 2021 at 9:00 a.m. ET.
      
      
    • A poster presentation entitled “Clinical Outcomes in Patients With and Without Pre-existing Neutralizing Antibodies to the Vector: 6-Month Data from the Phase 3 HOPE-B Gene Therapy Trial of Etranacogene Dezaparvovec” will be available on June 11, 2021 at 9:00 a.m. ET
      
      
• Goldman Sachs 42^nd Annual Global Healthcare Conference, June 8 - 11, 2021
  
  
  • Members of uniQure’s management team will participate in virtual one-on-one investor meetings throughout the day on Wednesday, June 2.
    
    
  • Matt Kapusta will participate in a fireside chat the same day at 4:40 to 5:20 p.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the Investors & Newsroom section of the uniQure website.
    
    
• uniQure’s Virtual Research & Development Day, June 22, 2021
  
  
  • uniQure will host a virtual Research & Development Day on June 22, 2021 at 8:30 to 11:30 a.m. ET to highlight new investments in its expanding gene therapy pipeline focusing on CNS and rare, liver-directed disorders, as well as new advancements in platform technology and manufacturing. Additional details can be accessed through the link displayed in the Investors & Newsroom section of the uniQure website.  
    
    
• Raymond James Virtual Human Health Innovation Conference, June 21 - 23, 2021
  
  
  • Members of uniQure’s management team will participate in virtual one-on-one investor meetings throughout the day on Wednesday, June 23.
    
    
  • Ricardo Dolmetsch, president of research and development, will participate in a panel entitled “Therapeutic Targets for Huntington’s Disease: We (Still) Down with HTT?”, from 9:20 to 10:10 a.m. ET.
    
    
  • A fireside chat with Matt Kapusta, chief executive officer, will take place the same day from 9:10 to 9:35 a.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the Investors & Newsroom section of the uniQure website.
    

About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases. www.uniQure.com

uniQure Contacts:

FOR INVESTORS:		FOR MEDIA:
Maria E. Cantor	Chiara Russo	Tom Malone
Direct: 339-970-7536	Direct: 617-306-9137	Direct: 339-970-7558
m.cantor@uniQure.com	c.russo@uniQure.com	t.malone@uniQure.com

FAQ

What is uniQure's R&D Day date in 2021?

uniQure will host its virtual Research & Development Day on June 22, 2021.

What key presentations will uniQure have at the EHA 2021 conference?

uniQure will present two encore presentations on June 11, 2021, showcasing clinical data from the pivotal Phase 3 HOPE-B trial.

When is the Jefferies Virtual Healthcare Conference?

The Jefferies Virtual Healthcare Conference takes place from June 1 to June 4, 2021.

What is the focus of uniQure's Research & Development Day?

The Research & Development Day will highlight new investments in gene therapy for CNS and liver-directed disorders.

When will uniQure present at the Goldman Sachs Global Healthcare Conference?

uniQure will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference from June 8 to June 11, 2021.